Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 9/20 | 0.49 |
| ▸ | GAA | P10253 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | GUSB | P08236 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6406084 | 0.90 | RAB9A (0.48) | ADORA2BGAAALDH1A1MEN1KMT2A | |
| SCHEMBL6409001 | 0.83 | ADORA2B (0.53) | ADORA2BGAAALDH1A1MEN1POLB | |
| SCHEMBL4646681 | 0.82 | GAA (0.51) | ADORA2BGAAALDH1A1POLBHSD17B10 | |
| SCHEMBL6404875 | 0.82 | ADORA2B (0.46) | ADORA2BGAAALDH1A1MEN1POLB | |
| SCHEMBL4650220 | 0.81 | USP2 (0.47) | GAAALDH1A1L3MBTL1HSD17B10 | |
| SCHEMBL6404869 | 0.78 | GAA (0.56) | ADORA2BGAAALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL6406082 | 0.74 | GAA (0.68) | ADORA2BGAAALDH1A1MEN1KMT2A | |
| SCHEMBL6405985 | 0.74 | GAA (0.49) | ADORA2BGAAALDH1A1HSD17B10MAPT | |
| SCHEMBL4744658 | 0.72 | GAA (0.66) | ADORA2BGAAALDH1A1L3MBTL1HSD17B10 | |
| SCHEMBL4649479 | 0.72 | GAA (0.54) | ADORA2BGAAALDH1A1L3MBTL1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050282838-A1 | Compounds, compositions, and methods | CYTOKINETICS, INC. | 2005-12-22 | — | — | US | claimed |
| US-20050282838-A1 | Compounds, compositions, and methods | CYTOKINETICS, INC. | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282838-A1 | Compounds, compositions, and methods | PCNA, MKI67, TP53 | ADORA2B 3513/4885GAA 349/4885ALDH1A1 1008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.